Insider Trading Alert - ARCW, EGBN And NHI Traded By Insiders

Yesterday, Dec. 1, 2015, 72 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $7.28 to $16,663,500.00.

Highlighted Stocks Traded by Insiders:

ARC Group Worldwide (ARCW) - FREE Research Report

Everest Hill Group Inc., who is 10% Owner at ARC Group Worldwide, bought 4,000 shares at $1.82 on Dec. 1, 2015. Following this transaction, the 10% Owner owned 9.0 million shares meaning that the stake was boosted by 0.04% with the 4,000-share transaction.

The shares most recently traded at $1.89, up $0.07, or 3.5% since the insider transaction. Historical insider transactions for ARC Group Worldwide go as follows:

  • 4-Week # shares bought: 10,300
  • 4-Week # shares sold: 124,275
  • 12-Week # shares bought: 10,300
  • 12-Week # shares sold: 124,275
  • 24-Week # shares bought: 10,300
  • 24-Week # shares sold: 124,275

The average volume for ARC Group Worldwide has been 40,500 shares per day over the past 30 days. ARC Group Worldwide has a market cap of $35.0 million and is part of the industrial goods sector and industrial industry. Shares are down 81.85% year-to-date as of the close of trading on Tuesday.

ARC Group Worldwide, Inc. manufactures and sells precision components, tooling products, flanges, fittings, and wireless equipment in the United States and internationally. It operates in four segments: Precision Components Group, 3DMT Group, Flanges and Fittings Group, and Wireless Group. Currently, there are 2 analysts who rate ARC Group Worldwide a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on ARCW - FREE

TheStreet Quant Ratings rates ARC Group Worldwide as a sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, disappointing return on equity, poor profit margins and generally disappointing historical performance in the stock itself. Get the full ARC Group Worldwide Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Eagle Bancorp (EGBN) - FREE Research Report

Brockett Charles C., who is EVP, Director of Operations at Eagle Bancorp, sold 2,715 shares at $55.13 on Dec. 1, 2015. Following this transaction, the EVP, Director of Operations owned 66,474 shares meaning that the stake was reduced by 3.92% with the 2,715-share transaction.

The shares most recently traded at $54.10, down $1.03, or 1.91% since the insider transaction. Historical insider transactions for Eagle Bancorp go as follows:

  • 4-Week # shares bought: 10,000
  • 4-Week # shares sold: 11,300
  • 12-Week # shares bought: 177,536
  • 12-Week # shares sold: 13,300
  • 24-Week # shares bought: 177,536
  • 24-Week # shares sold: 14,800

The average volume for Eagle Bancorp has been 116,200 shares per day over the past 30 days. Eagle Bancorp has a market cap of $1.8 billion and is part of the financial sector and banking industry. Shares are up 55.35% year-to-date as of the close of trading on Tuesday.

Eagle Bancorp, Inc. operates as a bank holding company for EagleBank that provides commercial and consumer banking services in the United States. The company has a P/E ratio of 23.6. Currently, there are 2 analysts who rate Eagle Bancorp a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on EGBN - FREE

TheStreet Quant Ratings rates Eagle Bancorp as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, impressive record of earnings per share growth, compelling growth in net income, good cash flow from operations and solid stock price performance. We feel its strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Eagle Bancorp Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

National Health Investors (NHI) - FREE Research Report

Mccabe Robert A Jr, who is Director at National Health Investors, bought 130 shares at $60.34 on Dec. 1, 2015. Following this transaction, the Director owned 8,095 shares meaning that the stake was boosted by 1.63% with the 130-share transaction.

The shares most recently traded at $60.77, up $0.43, or 0.71% since the insider transaction. Historical insider transactions for National Health Investors go as follows:

  • 4-Week # shares bought: 1,000
  • 4-Week # shares sold: 5,950
  • 12-Week # shares bought: 1,000
  • 12-Week # shares sold: 5,950
  • 24-Week # shares bought: 8,510
  • 24-Week # shares sold: 5,950

The average volume for National Health Investors has been 250,400 shares per day over the past 30 days. National Health Investors has a market cap of $2.3 billion and is part of the financial sector and real estate industry. Shares are down 12.79% year-to-date as of the close of trading on Tuesday.

National Health Investors Inc. is a real estate investment trust. It invests in the real estate markets of United States. The firm invests in the health care properties primarily in the long-term care and senior housing industries. The stock currently has a dividend yield of 5.63%. The company has a P/E ratio of 18.2. Currently, there is 1 analyst who rates National Health Investors a buy, 1 analyst rates it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on NHI - FREE

TheStreet Quant Ratings rates National Health Investors as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, growth in earnings per share, compelling growth in net income, good cash flow from operations and expanding profit margins. We feel its strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full National Health Investors Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

More from Markets

Don't Panic! The Risk of a Recession This Year Is Low

Don't Panic! The Risk of a Recession This Year Is Low

Even Standing Desk Company Varidesk Is Watching How the Trump Tariffs Play Out

Even Standing Desk Company Varidesk Is Watching How the Trump Tariffs Play Out

State Street Gets Pummeled on Software Deal; Pizza Wars Are Raging -- ICYMI

State Street Gets Pummeled on Software Deal; Pizza Wars Are Raging -- ICYMI

Schlumberger Stock Dips as Investors Ignore Start of 'Earnings Liftoff'

Schlumberger Stock Dips as Investors Ignore Start of 'Earnings Liftoff'

GSK Shares Climb as Board Is Said to Mull Breakup of Pharma Giant

GSK Shares Climb as Board Is Said to Mull Breakup of Pharma Giant